Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
作者信息
Guo Lixin, Xi Yue, Li Li, Guo Kunquan, Wu Jun, Xu Jiawei, Wang Yihua, Wu Guangyu, Si Si
机构信息
Beijing Hospital, Beijing, China.
The Third Affiliated Hospital of Jinzhou Medical University, Liaoning, China.
出版信息
Diabetes Obes Metab. 2024 Jul;26(7):2979-2983. doi: 10.1111/dom.15590. Epub 2024 Apr 10.
PMID:38600796
Abstract
摘要
相似文献
1
Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.中国2型糖尿病患者对度拉鲁肽的真实世界治疗满意度及其影响因素
Diabetes Obes Metab. 2024 Jul;26(7):2979-2983. doi: 10.1111/dom.15590. Epub 2024 Apr 10.
2
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.度拉糖肽（度易达）用于2型糖尿病
Am Fam Physician. 2017 Oct 15;96(8):540-542.
3
Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.利拉鲁肽对比度拉鲁肽在日本 2 型糖尿病患者中的真实世界疗效：一项回顾性研究。
Sci Rep. 2022 Jan 7;12(1):154. doi: 10.1038/s41598-021-04149-z.
4
Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.度拉糖肽治疗 2 型糖尿病的临床疗效及应答预测因素。
Pharmacol Res. 2020 Sep;159:104996. doi: 10.1016/j.phrs.2020.104996. Epub 2020 Jun 20.
5
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.每周一次的胰高血糖素样肽-1受体激动剂度拉糖肽对2型糖尿病患者动态血压和心率的影响。
Hypertension. 2014 Oct;64(4):731-7. doi: 10.1161/HYPERTENSIONAHA.114.03062. Epub 2014 Jun 30.
6
Two new doses of dulaglutide (Trulicity) for diabetes.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):168.
7
Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.在 Chinese 患者中，每周一次使用度拉鲁肽可实现糖化血红蛋白 <7.0%且不增加体重或低血糖的复合终点：一项事后分析。
J Diabetes Investig. 2020 May;11(3):647-652. doi: 10.1111/jdi.13187. Epub 2020 Jan 3.
8
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).安慰剂对照、随机试验，观察每周一次胰高血糖素样肽-1 受体激动剂度拉鲁肽添加至滴定剂量每日胰岛素甘精的疗效，该研究纳入了 2 型糖尿病患者（AWARD-9）。
Diabetes Obes Metab. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. Epub 2017 Apr 10.
9
Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.度拉糖肽对 2 型糖尿病患者血管健康指标的疗效：一项随机试验。
Cardiovasc Diabetol. 2021 Jan 4;20(1):1. doi: 10.1186/s12933-020-01183-5.
10
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的治疗模式：与每周一次的艾塞那肽和利拉鲁肽相比，度拉糖肽具有更高的依从性和持久性。
Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 Mar 16.
Zotero 插件